atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

Articles | December 19, 2022

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-year. There are currently no FDA-approved medications for CIAS, a major cause… Read More

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

Articles | December 16, 2022

NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) — atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for… Read More

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

Articles | November 29, 2022

– Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee – – He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries – –… Read More

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Articles | October 25, 2022

Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine). Last patient expected to be dosed this week, with the total number of patients expected to be around 100. Topline results expected around year-end 2022. PCN-101 is being investigated as a potentially rapid-acting therapeutic for treatment-resistant… Read More

atai Life Sciences Announces R&D Day Agenda

Articles | October 20, 2022

NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this event, management and scientific leaders will provide a comprehensive… Read More

atai Life Sciences to Participate in September Investor Events

Articles | September 7, 2022

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in Boston Format: Industry Panel… Read More

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

Articles | August 15, 2022

– Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections – Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI)… Read More

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

Articles | August 15, 2022

– Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments – Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward NEW YORK and BERLIN, Aug. Read More

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Articles | August 1, 2022

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022… Read More

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Articles | June 30, 2022

June 30, 2022 Dr. Chad Beyer will join as CEO on July 1, 2022   NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, depression, and pain, today announced… Read More